MedTrace Logo

Alpha-1 Antitrypsin Deficiency Adult Liver Study

NCT02014415 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-04-27

No results posted yet for this study

Summary

The investigators hypothesize that there is liver injury (inflammation, fibrosis, cirrhosis) in adults with Alpha-1 Antitrypsin Deficiency (AATD), which is asymptomatic, under-recognized, and undiagnosed. In addition, the investigators believe that the genetic and environmental factors that play an important role in the development of alpha-1 antitrypsin (AAT) liver disease, can be identified by comparing a cohort database of clinical disease information to linked biospecimen and DNA samples.

Conditions

  • Alpha-1 Antitrypsin Deficiency

Interventions

PROCEDURE

Liver Biopsy (Biopsy Group Only)

A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.

Sponsors & Collaborators

  • Alpha-1 Foundation

    collaborator OTHER

  • University of California

    collaborator OTHER

  • Boston University

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • University of Massachusetts, Worcester

    collaborator OTHER

  • St. Louis University

    lead OTHER

Principal Investigators

  • Jeffrey Teckman, MD · St. Louis University

  • Andrew A Wilson, MD · Alpha-1 Foundation

  • David A. Brenner, MD · The University of California, San Diego

  • Andrew A Wilson, MD · Boston University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02014415 on ClinicalTrials.gov